During the past decade, Bezirksklinikum Obermain conducted 2 clinical trials. In the 10-year time frame, 2 clinical trials started and 2 clinical trials were completed, i.e. on average, 100% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 2 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

According to Clinical.Site data, the most researched conditions in "Bezirksklinikum Obermain" are "Axial Spondyloarthritis" (1 trials), "Carcinoma, Non-Squamous Non-Small Cell Lung" (1 trials), "Plaque Psoriasis" (1 trials), "Psoriatic Arthritis" (1 trials) and "Rheumatoid Arthritis" (1 trials). Many other conditions were trialed in "Bezirksklinikum Obermain" in a lesser frequency.

Most popular intervention types in "Bezirksklinikum Obermain" are "Drug" (2 trials). Other intervention types were less common.

The name of intervention was led by "Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody" (1 trials), "Carboplatin" (1 trials), "Etanercept" (1 trials), "Nab-Paclitaxel" (1 trials) and "Pemetrexed" (1 trials). Other intervention names were less common.

The vast majority of trials in "Bezirksklinikum Obermain" are 2 trials for "All" genders.

Currently, there are NaN active trials in "Bezirksklinikum Obermain". undefined are not yet recruiting, undefined are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 2 completed trials in Bezirksklinikum Obermain, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Bezirksklinikum Obermain, 0 "Phase 1" clinical trials were conducted, 0 "Phase 2" clinical trials and 1 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".